trending Market Intelligence /marketintelligence/en/news-insights/trending/115IF16lPFL0bjmb4p-EHw2 content esgSubNav
In This List

Selecta Biosciences chief business officer resigns

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Selecta Biosciences chief business officer resigns

Selecta Biosciences Inc. said Peter Keller resigned as chief business officer, effective Dec. 18.

Keller will resign as an employee and from all other offices of the company, effective Dec. 31.

Keller has agreed to provide consulting and advisory services to Selecta for one year following his resignation.